Somnus Therapeutics was a private specialty pharmaceutical company based in Bedminster, United States. The company's lead product, SKP-1041, was a controlled-release formulation of an established non-benzodiazepine hypnotic, licensed from SkyePharma, aimed at preventing mid-night awakenings without next-day hangovers
Insomnia
CTI LSF I
Co-Lead
Director
February 9, 2010
Liquidated in 2015
Series A
Somnus Therapeutics' lead asset could addresses the two key issues of existing insomnia treatments, patients waking up at the middle of the night and waking up the next day drowsy
